STOCK TITAN

Lifeloc now expects limited SpinDetect launch in Q4 2027

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Lifeloc Technologies, Inc. (LCTC) reported third-quarter 2026 revenue of $2,521,874, up 12% from $2,257,448 a year earlier, and a net loss of ($84,931), versus ($263,439). Diluted loss per share was ($0.03) versus ($0.10); gross margin was 43% versus 40%. For the first nine months, revenue was $7,260,643 versus $6,753,858, and net loss was ($371,974) versus ($949,764).

Lifeloc now expects a limited commercial launch of SpinDetect in Q4 2027, revised from its prior Q1 2027 expectation. Beta testing focused on delta-9-THC is planned with a prototype reader, with final component optimization underway under a signed agreement. The company is redirecting some resources to core alcohol products and expects upgrades to generate revenue to help fund SpinDetect; the revised timeline depends on that revenue and timely capital access. Nine-month net cash used in operating activities was $14,618, versus $578,437 in 2025.

3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointThird-quarter revenue increased 12% to $2,521,874 year over year.
  • Moderate pointNine-month net loss narrowed to ($371,974) from ($949,764).
  • Moderate pointNine-month net cash used in operating activities was $14,618, versus $578,437 in 2025.

Negative

  • Moderate point. Forward-looking: it has not happened yet and may not happen.SpinDetect’s limited commercial launch expectation shifted from Q1 2027 to Q4 2027.

Filing Explained

Lifeloc reports $500,000 of related-party term-loan proceeds during the first nine months of 2026 and, at September 30, 2026, $59,396 in current and $440,604 in noncurrent related-party loan payables; this was debt financing, not an issuance of shares.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Third-quarter revenue $2,521,874 Three months ended September 30, 2026; $2,257,448 in 2025; revenue increased 12%.
Third-quarter net loss ($84,931) Three months ended September 30, 2026; ($263,439) in 2025.
Diluted loss per share ($0.03) Three months ended September 30, 2026; ($0.10) in 2025.
Nine-month revenue $7,260,643 Nine months ended September 30, 2026; $6,753,858 in 2025.
Nine-month net loss ($371,974) Nine months ended September 30, 2026; ($949,764) in 2025.
Third-quarter gross margin 43% Three months ended September 30, 2026; 40% in 2025.
Net cash used in operating activities $14,618 Nine months ended September 30, 2026; $578,437 in 2025.
microfluidic disk technical
"completed the design of the SpinDetect™ microfluidic disk"
liquid chromatography-mass spectrometry (LC-MS) technical
"validated against liquid chromatography-mass spectrometry (LC-MS)"
An analytical lab technique that first separates a mixture into its components (like passing a soup through finer and finer sieves) and then measures each component’s unique mass signature (like taking a molecular fingerprint). Investors care because LC-MS is a primary tool for verifying drug purity, detecting trace contaminants, measuring biomarker levels in trials, and supporting regulatory filings—results that affect a product’s safety, approval prospects, and commercial value.
limit of detection technical
"confirming a limit of detection of approximately 10 ng/ml"
Limit of detection is the smallest amount of a substance or signal that a test or instrument can reliably tell apart from no presence at all. Think of it as the faintest whisper a microphone can pick up before it sounds like silence. For investors, it matters because a lower limit means a test or product can detect earlier or smaller changes, affecting clinical claims, regulatory approval chances, market adoption, and revenue potential.
subordinated debentures financial
"SUBORDINATED DEBENTURES PAYABLE"
A subordinated debenture is a type of long-term loan a company issues that ranks below other debts when paying creditors, so holders are paid only after higher-priority lenders if the company defaults. It matters to investors because this lower repayment priority raises the risk of loss, which companies typically offset by offering higher interest, making it a trade-off between yield and safety—like standing later in line for a bigger tip.
Revenue $2,521,874 Increased 12% from $2,257,448 in the third quarter of 2025.
Net loss ($84,931) Narrowed from ($263,439) in the third quarter of 2025.
Diluted loss per share ($0.03) Compared with ($0.10) in the third quarter of 2025.
Gross margin 43% Compared with 40% in the third quarter of 2025.
Nine-month revenue $7,260,643 Compared with $6,753,858 in the first nine months of 2025.
Nine-month net loss ($371,974) Compared with ($949,764) in the first nine months of 2025.
Guidance

Lifeloc expects a limited commercial launch of SpinDetect in Q4 2027, revised from its prior Q1 2027 expectation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were LCTC’s third-quarter 2026 revenue and net loss?

Lifeloc reported revenue of $2,521,874 and a net loss of ($84,931) for the third quarter of 2026. Revenue increased 12% from $2,257,448, while the net loss was narrower than ($263,439) in the prior-year quarter.

When does Lifeloc expect to launch SpinDetect?

Lifeloc expects a limited commercial launch in Q4 2027, revised from its prior Q1 2027 expectation.

What is Lifeloc testing in the SpinDetect beta program?

The planned beta testing focuses on delta-9-THC detection using a prototype reader. Final component optimization is underway under a signed beta-testing agreement.

How did Lifeloc validate SpinDetect’s oral-fluid test results?

Lifeloc says it validated results against liquid chromatography-mass spectrometry (LC-MS) using real-world human saliva samples, confirming a limit of detection of approximately 10 ng/ml.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001493137 0001493137 2026-11-16 2026-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

 

FORM 8-K

 

 CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 16, 2026

 

LIFELOC TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

Colorado   000-54319   84-1053680
(State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification Number)

 

12441 West 49th Ave., Unit 4    
Wheat Ridge, CO   80033
(Address of Principal Executive Offices)   (Zip Code)

 

(303) 431-9500

(Registrant’s telephone number, including area code)

   

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 
 

 

Item 2.02Results of Operations and Financial Condition.

 

On November 16, 2026, Lifeloc Technologies, Inc. (the “Company”) issued a press release announcing its operating results for the period ended September 30, 2026. This press release was made available on the Company’s website as of November 16, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.

 

The information in this Form 8-K, including the exhibit attached hereto, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended, unless expressly set forth by specific reference in such filing that such information is incorporated by reference therein.

 

Item 9.01 Financial Statements and Exhibits.
   

(d) Exhibits.

   

Exhibit No. Description
   
99.1 Press Release, dated November 16, 2026, issued by the Company
   
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
   

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:  November 16, 2026 LIFELOC TECHNOLOGIES, INC.
     
  By:   /s/ Vern D. Kornelsen
    Chief Financial Officer and Secretary

 

 

 

 

Exhibit 99.1

 

Lifeloc Reports Third Quarter 2026 Results

 

WHEAT RIDGE, Colo., November 16, 2026 -- Lifeloc Technologies, Inc. (OTCID: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the quarter ended September 30, 2026.

 

Third Quarter Financial Highlights

 

Lifeloc posted quarterly net revenue of $2.522 million in the third quarter of 2026, resulting in a quarterly net loss of $(85) thousand, or $(0.03) per diluted share. These results compare to net revenue of $2.257 million and quarterly net loss of $(263) thousand, or $(0.10) per diluted share in the third quarter of 2025. Revenue for the quarter grew 12% versus the third quarter last year. For the first nine months of 2026, net revenue was $7.261 million and net loss was $(372) thousand, or $(0.14) per diluted share, compared with net revenue of $6.754 million and net loss of $(950) thousand, or $(0.35) per diluted share, for the same period in 2025. Total gross margin in the third quarter rose to 43% versus 40% for the same quarter last year. For the first nine months of 2026, gross margin was 44% versus 41% for the same period last year, with price increases and a favorable product mix contributing to the higher margins. The research and development investment for the quarter remained high at $506 thousand, primarily for SpinDetect™ analyzer development, resulting in the current period loss.

 

Alcohol Detection Products

 

We believe our core alcohol detection product lineup is strong. The L-series LX9 and LT7 units have features and performance that drive market penetration by addressing previously unmet market needs such as smartphone pairing, wider temperature use ranges and fast customization that incorporates local languages. We expect that sales of our newer L-series devices will be incremental to FC-series devices rather than displacing FC sales. The L-series devices have been certified to meet the requirements of most modern registration standards, such as the latest AS 3547:2019 standards for Breath Alcohol Detectors from SAI Global (formerly Standards Australia International). Our FC-series devices remain popular with many law enforcement and international organizations. Our Easycal® automated calibration station, the only automated calibration available for portable breath alcohol testers, builds valuable protection around our brand and has contributed to market share gains across the board, especially for our workplace Phoenix® 6.0 BT and EV 30 devices.

 

 
 

SpinDetect™ Analyzer Platform

 

We believe our most significant long-term opportunity lies at the intersection of the global need for rapid, quantitative drug detection and our proven expertise in portable testing instrumentation. Our SpinDetect™ Centrifugal Drug Analyzer — sometimes referred to as "Lab on a Disk" — is designed to address this need, enabling rapid, on-site, quantitative drug testing for use at roadside, in emergency rooms, forensic labs, and workplace testing sites. We have demonstrated the platform's ability to effectively detect delta-9-THC, cocaine, fentanyl, amphetamine/methamphetamine, morphine, MDMA, and benzodiazepines from oral fluid. We have validated our test results against liquid chromatography-mass spectrometry (LC-MS) — the definitive laboratory standard — using real-world human saliva samples, confirming a limit of detection of approximately 10 ng/ml.

 

We have completed the design of the SpinDetect™ microfluidic disk, with all analytical chemistry now occurring on the disk after sample introduction. We will be initiating beta testing of the oral-fluid analyzer focused on delta-9-THC detection using a prototype reader, with final component optimization underway, under a signed beta-testing agreement. The full commercial product is expected to measure delta-9-THC, followed by a multi-drug panel release. We previously anticipated a limited commercial launch of SpinDetect in Q1 of 2027; we now expect the limited commercial launch to occur in Q4 of 2027. In recent periods we devoted a substantial portion of our engineering and development resources to SpinDetect and, as a result, deferred upgrades and enhancements to our core breath alcohol testing products. We are redirecting a portion of those resources to our core products in the near term and will be conducting beta testing and the validation of SpinDetect with our current staff rather than with additional personnel. The upgrades to our core products will allow us to enter additional markets and generate incremental revenue, which we expect will help fund the work required to complete and bring SpinDetect to market.

 

Following the limited commercial launch, we plan to expand into additional drug panels and sample types, including blood and breath — the latter integrated with our LX9 breathalyzer. The SpinDetect™ reader is designed to accept multiple disk formats, which may also enable future applications beyond drug testing, such as detection of food-safety markers and environmental contaminants; these applications would require additional research, regulatory clearances, and potential expansion of our existing license rights. Our revised timeline and continued progress toward commercialization depend on our ability to generate the anticipated incremental revenue from our core products and on timely access to capital to support fabrication, validation, regulatory preparation, and market introduction. There can be no assurance that the launch will occur when currently expected.

 

 
 

“We are raising the priority of our alcohol testing research and development projects that can have a quick, positive impact on cash flow. While we had deferred some core business opportunities, transformational AI tools have reduced the cost and timeline for hardware and firmware upgrades, raising the return on investment for these projects,” commented Dr. Wayne Willkomm, President and CEO. “Using advances in our core products to fund the big growth opportunity of the SpinDetect™ Centrifugal Drug Analyzer is consistent with our desire to fund from operations as best as we can.”

 

 

 

 
 

About Lifeloc Technologies

 

Lifeloc Technologies, Inc. (OTCID: LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our website, www.lifeloc.com/investor.

 

Forward Looking Statements

 

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, performance, expectations about new and existing products, market demand, economic conditions, acceptance of new and existing products, technologies and opportunities, market size and growth, market liquidity for our shares, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled “Risk Factors” in our SEC filings.

 

Phoenix® and Easycal® are registered trademarks of Lifeloc Technologies, Inc.

 

SpinDetect™ is a trademark of Lifeloc Technologies, Inc.

 

Amy Evans 
Lifeloc Technologies, Inc. 
http://www.lifeloc.com 
(303) 431-9500

 

 
 

  

 LIFELOC TECHNOLOGIES, INC.

Condensed Balance Sheets (Unaudited)

 

                 
ASSETS            
CURRENT ASSETS:   September 30, 2026     December 31, 2025  
Cash and cash equivalents   $ 930,539     $ 746,001  
Accounts receivable, net     785,442       772,380  
Inventories, net     2,678,034       2,633,614  
Federal and state income taxes receivable     55,381       55,981  
Prepaid expenses and other     96,747       60,825  
      Total current assets     4,546,143       4,268,801  
                 
PROPERTY, PLANT AND EQUIPMENT:                
Land     317,932       317,932  
Building     1,928,795       1,928,795  
Real-time Alcohol Detection And Recognition equipment and software     569,448       569,448  
Production equipment, software and space modifications     1,366,539       1,366,539  
Office equipment, software and space modifications     197,686       197,686  
Sales and marketing equipment and space modifications     230,543       225,173  
Research and development equipment, software and space modifications     1,444,531       1,213,195  
Research and development equipment, software and space modifications not in service     -       19,595  
Less accumulated depreciation     (3,745,873)       (3,538,455 )
     Total property and equipment, net     2,309,601       2,299,908  
                 
OTHER ASSETS:                
Patents, net     65,324       71,039  
Deposits and other     81,560       46,820  
     Total other assets     146,884       117,859  
     Total assets   $ 7,002,628     $ 6,686,568  
CURRENT LIABILITIES:                
Accounts payable   $ 543,342     $ 301,627  
Term loan payable, current portion     56,123       54,850  
Term loan payable (Related party), current portion     59,396       —  
Subordinated debentures payable, current portion     36,897       33,371  
Customer deposits     2,689       25,694  
Accrued expenses     344,565       321,112  
Deferred revenue, current portion     60,959       53,716  
Product warranty reserve     46,500       46,500  
      Total current liabilities     1,150,471       836,870  
                 
TERM LOAN PAYABLE, net of current portion and debt issuance costs     1,016,171       1,058,426  
                 
TERM LOAN PAYABLE (Related Party), net of current portion and debt issuance costs     440,604       —  
                 
SUBORDINATED DEBENTURES PAYABLE, net of current portion and debt issuance costs     653,219       681,343  
                 
DEFERRED REVENUE, net of current portion     10,359       6,151  
      Total liabilities     3,270,824       2,582,790  
                 
COMMITMENTS AND CONTINGENCIES (Note 6)             —  
                 
STOCKHOLDERS’ EQUITY:                
Common stock, no par value; 50,000,000 shares authorized, 2,752,616 shares outstanding     5,934,314       5,934,314  
Accumulated deficit     (2,202,510)       (1,830,536 )
      Total stockholders’ equity     3,731,804       4,103,778  
      Total liabilities and stockholders’ equity   $ 7,002,628     $ 6,686,568  

 

 

 
 

LIFELOC TECHNOLOGIES, INC.

Condensed Statements of Profit (Loss) (Unaudited)

         
   Three Months Ended September 30, 
REVENUES:  2026   2025 
Product sales  $2,512,530   $2,241,331 
Royalties   9,344    16,117 
Rental income   —    — 
Total   2,521,874    2,257,448 
           
COST OF SALES   1,431,792    1,350,755 
           
GROSS PROFIT   1,090,082    906,693 
           
OPERATING EXPENSES:          
Research, development, and sustaining engineering   505,982    458,747 
Sales and marketing   314,948    341,567 
General and administrative   319,223    340,705 
Total   1,140,153    1,141,019 
           
OPERATING (LOSS)   (50,071)   (234,326)
           
OTHER INCOME (EXPENSE):          
Interest income   8,734    7,840 
Interest expense   (43,594)   (36,953)
Total   (34,860)   (29,113)
           
NET (LOSS) BEFORE PROVISION FOR TAXES   (84,931)   (263,439)
           
BENEFIT FROM FEDERAL AND STATE INCOME TAXES   —    — 
           
NET (LOSS)  $(84,931)  $(263,439)
           
NET (LOSS) PER SHARE, BASIC  $(0.03)  $(0.10)
           
NET (LOSS) PER SHARE, DILUTED  $(0.03)  $(0.10)
           
WEIGHTED AVERAGE SHARES, BASIC   2,752,616    2,752,616 
           
WEIGHTED AVERAGE SHARES, DILUTED   2,752,616    2,752,616 
           

 

 

 
 

LIFELOC TECHNOLOGIES, INC.

Condensed Statements of Profit (Loss) (Unaudited)

  

         
   Nine Months Ended September 30, 
REVENUES:  2026   2025 
Product sales  $7,236,986   $6,695,638 
Royalties   23,657    41,588 
Rental income   —    16,632 
Total   7,260,643    6,753,858 
           
COST OF SALES   4,090,961    4,014,000 
           
GROSS PROFIT   3,169,682    2,739,858 
           
OPERATING EXPENSES:          
Research, development, and sustaining engineering   1,480,708    1,551,689 
Sales and marketing   949,145    1,015,651 
General and administrative   1,021,478    1,065,657 
Total   3,451,331    3,632,997 
           
OPERATING (LOSS)   (281,649)   (893,139)
           
OTHER INCOME (EXPENSE):          
Interest income   24,121    31,128 
Interest expense   (114,446)   (87,753)
Total   (90,325)   (56,625)
           
NET (LOSS) BEFORE PROVISION FOR TAXES   (371,974)   (949,764)
           
BENEFIT FROM FEDERAL AND STATE INCOME TAXES   —    — 
           
NET (LOSS)  $(371,974)  $(949,764)
           
NET (LOSS) PER SHARE, BASIC  $(0.14)  $(0.35)
           
NET (LOSS) PER SHARE, DILUTED  $(0.14)  $(0.35)
           
WEIGHTED AVERAGE SHARES, BASIC   2,752,616    2,733,490 
           
WEIGHTED AVERAGE SHARES, DILUTED   2,752,616    2,733,490 
           

 

 

 
 

 

LIFELOC TECHNOLOGIES, INC.

Condensed Statements of Changes in Stockholders’ Equity (Unaudited)

For the Three and Nine Months Ended September 30, 2026 and 2025

 

 

                 
   2026 
   Common Stock Shares   Common Stock Amount   Accumulated Deficit   Total 
Beginning balance, December 31, 2025   2,752,616   $5,934,314   $(1,830,536)  $4,103,778 
Net (loss)   —    —    (152,713)   (152,713)
Ending balance, March 31, 2026   2,752,616    5,934,314    (1,983,249)   3,951,065 
Net (loss)   —    —    (134,330)   (134,330)
Ending balance, June 30, 2026   2,752,616    5,934,314    (2,117,579)   3,816,735 
Net (loss)   —    —    (84,931)   (84,931)
Ending balance, September 30, 2026   2,752,616   $5,934,314   $(2,202,510)  $3,731,804 

 

 

                 
   2025 
   Common Stock Shares   Common Stock Amount   Accumulated Deficit   Total 
Beginning balance, December 31, 2024   2,664,116   $5,586,014   $639,863   $6,225,877 
Issuance of shares from option exercise   88,500    336,300    —    336,300 
Warrants issued with subordinated debenture   —    12,000    —    12,000 
Net (loss)   —    —    (292,686)   (292,686)
Ending balance, March 31, 2025   2,752,616    5,934,314    347,177    6,281,491 
Net (loss)   —    —    (393,639)   (393,639)
Ending balance, June 30, 2025   2,752,616    5,934,314    (46,462)   5,887,852 
Net (loss)   —    —    (263,439)   (263,439)
Ending balance, September 30, 2025   2,752,616   $5,934,314   $(309,901)  $5,624,413 

  

 

 
 

LIFELOC TECHNOLOGIES, INC.

Condensed Statements of Cash Flows (Unaudited)

         
   Nine months Ended September 30, 
CASH FLOWS FROM OPERATING ACTIVITIES:  2026   2025 
Net (loss)  $(371,974)  $(949,764)
Adjustments to reconcile net (loss) to net cash (used in) operating activities-          
   Provision for doubtful accounts, net change   —    1,500 
   Depreciation and amortization   213,133    325,095 
   Amortization of debt issuance costs   18,153    11,937 
Changes in operating assets and liabilities-          
   Accounts receivable   (13,062)   (133,415)
   Inventories   (44,420)   134,239 
   Federal and state income taxes receivable   600    24,729 
   Prepaid expenses and other   (35,922)   (102,583)
   Deposits and other   (34,740)   (34,559)
   Accounts payable   241,715    133,342 
   Customer deposits   (23,005)   (25,885)
   Accrued expenses   23,453    34,753 
   Deferred revenue   11,451    2,174 
Net cash (used in) operating activities   (14,618)   (578,437)
           
CASH FLOWS (USED IN) INVESTING ACTIVITIES:          
Purchases of sales and marketing equipment   (5,370)   (39,510)
Purchases of research and development equipment, software and space modifications   (211,741)   (310,646)
Net cash (used in) investing activities   (217,111)   (350,156)
           
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:          
Principal payments made on term loan   (42,592)   (41,356)
Proceeds from issuance of subordinated debenture   —    75,000 
Proceeds (related party) from issuance of term loan   500,000    — 
Principal payments made on subordinated debentures   (41,141)   — 
Proceeds from issuance of shares from option exercise        336,300 
Net cash provided from financing activities   416,267    369,944 
           
NET INCREASE (DECREASE) IN CASH   184,538    (558,649)
           
CASH, BEGINNING OF PERIOD   746,001    1,243,746 
           
CASH, END OF PERIOD  $930,539   $685,097 
           
SUPPLEMENTAL INFORMATION:          
Cash paid for interest  $96,292   $75,816 
           
           
Income tax refund received  $—   $24,729 
           
Non-cash financing and investing activities: warrants issued with subordinated debenture  $—   $12,000 

 

 

 

 

 

Filing Exhibits & Attachments

4 documents

Keep reading